Spots Global Cancer Trial Database for locally advanced solid tumors
Every month we try and update this database with for locally advanced solid tumors cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors | NCT06364696 | Solid Tumor | ASP4396 | 18 Years - | Astellas Pharma Inc | |
| Imaging of Advanced Tumours Using [131]I-IAZA | NCT03427320 | Locally Advance... Metastatic Soli... | [131]I-IAZA | 18 Years - 75 Years | University of Alberta | |
| A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors | NCT03646071 | Locally Advance... Metastatic Soli... | RX108 | 18 Years - | NeuPharma, Inc. | |
| Imaging of Advanced Tumours Using [131]I-IAZA | NCT03427320 | Locally Advance... Metastatic Soli... | [131]I-IAZA | 18 Years - 75 Years | University of Alberta | |
| Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors | NCT02045602 | Locally Advance... Metastatic Soli... Pancreatic Aden... | VCN-01 Gemcitabine Abraxane® | 18 Years - | Theriva Biologics SL | |
| A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors | NCT03059823 | Locally Advance... Metastatic Soli... | retifanlimab | 18 Years - | Incyte Corporation | |
| This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors. | NCT03573544 | Metastatic Soli... Locally Advance... | OBI-888 OBI-888 Globo H IHC Ass... | 18 Years - | OBI Pharma, Inc | |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | NCT06031441 | Locally Advance... Recurrent Solid... Metastatic Soli... | RO7566802 Atezolizumab | 18 Years - | Genentech, Inc. | |
| A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors | NCT02869295 | Unspecified Adu... | NKTR-214 | 18 Years - | Nektar Therapeutics | |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors | NCT02867007 | Solid Tumor Cancer Carcinoma | KHK2455 Mogamulizumab | 18 Years - | Kyowa Kirin Co., Ltd. | |
| A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors | NCT06364696 | Solid Tumor | ASP4396 | 18 Years - | Astellas Pharma Inc | |
| This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors. | NCT03573544 | Metastatic Soli... Locally Advance... | OBI-888 OBI-888 Globo H IHC Ass... | 18 Years - | OBI Pharma, Inc | |
| Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors | NCT00492830 | Cancer Neoplasm Metast... | TRC093 recombin... | 18 Years - | Tracon Pharmaceuticals Inc. | |
| A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors | NCT03059823 | Locally Advance... Metastatic Soli... | retifanlimab | 18 Years - | Incyte Corporation | |
| A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors | NCT02869295 | Unspecified Adu... | NKTR-214 | 18 Years - | Nektar Therapeutics | |
| A Study of ASP1012 in Adults With Solid Tumors | NCT06171178 | Solid Tumor | ASP1012 Pembrolizumab | 18 Years - | Astellas Pharma Inc |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
